Chembio Diagnostics shares jump 200% on $28.3m order
Chembio Diagnostics shares jump 200% on $28.3m order
By Chris Wack
克里斯·瓦克(Chris Wack)著
Chembio Diagnostics Inc. shares nearly doubled to $4.03 in premarket trading after the company said it received a $28.3 million purchase order from Bio-Manguinhos for Chembio's DPP SARS-CoV-2 antigen tests for delivery during 2021.
Chembio Diagnostics Inc.的股價在盤前交易中幾乎翻了一番，至4.03美元，此前該公司表示，它收到了Bio-Manguinhos價值2,830萬美元的訂單，將於2021年交付Chembio的DPP SARS-CoV-2抗原檢測。
Chembio Diagnostics Inc's stock price continues to soar during trading hours on Wednesday
Chembio Diagnostics Inc.的股價在週三的交易時段繼續飆升
The company said its antigen test is designed to detect the SARS-CoV-2 antigen, which indicates an active positive test result, in 20 minutes using a minimally invasive nasal swab.
該公司表示，其抗原檢測旨在使用微創鼻拭子在20分鐘內檢測出SARS-CoV-2抗原，這表明檢測結果為積極陽性。
Bio-Manguinhos, a subsidiary of the Oswaldo Cruz Foundation, is responsible for the development and production of vaccines, diagnostics, and biopharmaceuticals, primarily to meet demands of Brazil's national public health system.
Bio-Manguinhos是奧斯瓦爾多·克魯斯基金會(Oswaldo Cruz Foundation)的子公司，負責疫苗、診斷和生物製藥的開發和生產，主要是為了滿足巴西國家公共衞生系統的需求。
Write to Chris Wack at chris.wack@wsj.com
寫信給克里斯·瓦克(chris.wack@wsj.com)
(END) Dow Jones Newswires
(完)道瓊通訊社
July 21, 2021 09:24 ET (13:24 GMT)
2021年7月21日09：24美國東部時間(格林尼治標準時間13：24)
Copyright (c) 2021 Dow Jones & Company, Inc.
版權所有(C)2021年道瓊斯公司